Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Asset Utilization Ratio (2016 - 2025)

ImmunityBio (IBRX) has disclosed Asset Utilization Ratio for 11 consecutive years, with 0.18 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Utilization Ratio rose 888.83% to 0.18 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.18, a 888.83% increase, with the full-year FY2024 number at 0.03, up 2215.61% from a year prior.
  • Asset Utilization Ratio was 0.18 for Q3 2025 at ImmunityBio, up from 0.16 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.18 in Q3 2025 to a low of 0.0 in Q1 2021.
  • A 5-year average of 0.03 and a median of 0.0 in 2021 define the central range for Asset Utilization Ratio.
  • Peak YoY movement for Asset Utilization Ratio: crashed 81.16% in 2021, then surged 13527.09% in 2025.
  • ImmunityBio's Asset Utilization Ratio stood at 0.0 in 2021, then tumbled by 61.68% to 0.0 in 2022, then soared by 97.87% to 0.0 in 2023, then surged by 2871.13% to 0.04 in 2024, then surged by 354.38% to 0.18 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Asset Utilization Ratio are 0.18 (Q3 2025), 0.16 (Q2 2025), and 0.09 (Q1 2025).